160 Health International Limited
健康160国际有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2656)

VOLUNTARY ANNOUNCEMENT
INTRODUCTION OF A NEW BUSINESS INTEGRATING HEALTHCARE WITH AI COMPUTING POWER

This announcement is made by 160 Health International Limited (the "**Company**", together with its subsidiaries and consolidated affiliated entities, the "**Group**") on a voluntary basis to provide shareholders (the "**Shareholders**") and potential investors of the Company an update on the latest business development of the Group.

The board (the "**Board**") of directors (the "**Directors**") of the Company is pleased to announce that the Group, through a domestic subsidiary, has recently completed the delivery of an integrated solution with a total amount of RMB12.2 million (the "**Order**") to a big healthcare enterprise focusing on the research and development of smart wearable health devices (the "**Client**"), and obtained the acceptance document from the Client. To the best of the knowledge, information and belief of the Board, the Client and its ultimate beneficial owners are third parties independent of the Company and its connected persons (as defined under the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**")).

Under the Order, the Group provided the Client with an integrated solution that includes a smart health monitoring system, computing power infrastructure, and integrated debugging services (the "**Solution**"). Upon completion of the delivery, the Solution will enable real-time access, cleansing and storage of high-frequency vital sign data from the Client's extensive network of terminal devices. It will also utilize computing power to support core functions such as AI-driven health inference, early risk warning, and user health profile management.

I. BUSINESS BACKGROUND

The Group has a long-standing presence in the internet healthcare sector, accumulating extensive experience in healthcare and wellness services and holding numerous intellectual property rights, including invention patents and software copyrights. Building on its proprietary platform, the Group has upgraded and launched the 160AI Hospital through the deep integration of AI applications, and innovatively launched the "160AI Hospital" operational collaboration business model, continuously advancing the practical application of AI agents in medical scenarios. Currently, the Group has established an integrated model of "platform + AI agent + operations", fully embedding AI agents into its internal operational system and applying them across product research and development, content creation, and customer service, which significantly enhances the Group's overall operational efficiency and professional service capabilities.

To seize market opportunities from the convergence of AI technology and healthcare, the Group has sought to expand its existing operations by integrating its proprietary smart health monitoring system with computing power infrastructure. This has resulted in an integrated solution of "healthcare AI agent + hardware + integrated debugging service", offering AI healthcare products bundled with computing power infrastructure to healthcare and wellness clients, thereby further enriching the product matrix of the Group.

II. STRATEGIC BUSINESS VALUE AND DEVELOPMENT PROSPECTS

The Board believes that the successful delivery and acceptance of the Solution represent an important exploration and a key milestone for the Group's new business direction in integrating healthcare with AI computing power. The Group notes that, as the application of AI technology in the healthcare and wellness industry continues to deepen and improve, there is a growing demand from downstream clients for integrated delivery of "AI application + computing power infrastructure". This is especially true in scenarios such as smart wearable health monitoring and chronic disease management, where the coordinated deployment of AI software platform and computing power infrastructure has become essential for healthcare enterprise clients to achieve a business closed-loop. By combining its proprietary software capabilities with computing power infrastructure, the Group is able to provide downstream clients in need with more valuable digital healthcare and wellness solutions, thereby further broadening its business boundaries and service depth, advancing towards its strategic goal of evolving from a "comprehensive digital medical and healthcare service platform" into a "medical AI intelligent ecosystem infrastructure and service provider", while also diversifying its revenue streams.

III. RISK WARNING

The Company advises the Shareholders and potential investors that the Group's business development in integrating healthcare with AI computing power is still in its early stage. The delivery and acceptance of the Order represent only the fulfillment of a single business order, and do not yet establish a scalable and sustainable revenue model. While the Company anticipates that the integrated solution may bring a certain revenue contribution to the Group in the future, the exact amount and the impact on the overall financial position cannot be accurately estimated, nor can there be any assurance that it will bring continuous revenue or profit contribution to the Group in the future.

The Order and the transaction thereunder do not constitute a notifiable transaction under Chapter 14 of the Listing Rules, nor do they constitute a connected transaction under Chapter 14A of the Listing Rules.

Shareholders and prospective investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
160 Health International Limited
Mr. LUO Ningzheng
Chairman of the Board, Executive Director
and Chief Executive Officer

Hong Kong, September 14, 2026

As of the date of this announcement, the Board comprises (i) Mr. LUO Ningzheng, Mr. JI Cuilin, Mr. HUANG Lang and Mr. WANG Lifa as executive Directors; (ii) Mr. LIU Haibin as non-executive Director; and (iii) Mr. WANG Huan, Dr. XU Weiguo and Dr. FAN Ming as independent non-executive Directors.